Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?

Basic and Clinical Pharmacology and Toxicology

Volumn 117, Issue 3, 2015, Pages 213-214

  Łukasik Głebocka, Magdalena ^a,b   Sommerfeld, Karina ^a   Tezyk, Artur ^a   Panieński, Paweł ^a   Zaba, Czesław ^a   Zielińska Psuja, Barbara ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Raszeja's Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; MIDAZOLAM; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DELIRIUM; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MIDDLE AGED; POST INJECTION DELIRIUM SEDATION SYNDROME; PRIORITY JOURNAL; RESPIRATORY TRACT INTUBATION; SCHIZOPHRENIA; SINUS TACHYCARDIA; TANDEM MASS SPECTROMETRY; UPPER RESPIRATORY TRACT OBSTRUCTION; BLOOD; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; SYNDROME; UNCONSCIOUSNESS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, LIQUID; DELAYED-ACTION PREPARATIONS; DELIRIUM; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; SCHIZOPHRENIA; SYNDROME; TANDEM MASS SPECTROMETRY; UNCONSCIOUSNESS;

EID: 84938547994     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12394     Document Type: Article

References (11)

1. Brunton L, Parker K, Blumenthal D, Buxton I. Goodman and Gilman's Manual of Pharmacology and Therapeutics. McGrawHill Medical, International Edition, New York, 2008.
2. Heres S, Kraemer S, Bergstrom RF, Detke HC. Pharmacokinetics of olanzapine long-action injection: the clinical perspective. Int Clin Psychopharmacol 2014;29:299-312.
3. Mc Donnell DP, Detke H, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 2010;10:45.
4. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10:43.
5. Fisher DS, Partridge SJ, Handley A, Couchman L, Morgan PE, Flanagan RJ. LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood. Forensic Sci Int 2013;229:145-50.
6. Chue P, Chue J. A review of olanzapine pamoate. Expert Opin Pharmacother 2012;13:166-70.
7. Kane JM, Detke HC, Naber D, Sethurman G, Lin DY, Bergstrom RF et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9.
8. Duran-Sindreu SF, Grasa-Bello E, Corripio-Collado I, Sauras-Quetcuti RB, Keymer-Gausset A, Roldan-Bejarano A et al. Olanzapine long-acting post-injection syndrome: a case report and brief review. Actas Esp Psiquiatr 2013;41:60-2.
9. Buts K, Van Hecke J. Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry. Tijdschr Psychiatr 2014;56:273-6.
10. Vodovar D, Malissin I, Deye N, Baud FJ, Megarbane B. Olanzapine post-injection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department. J Emerg Med 2014;47:23-4.
11. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm357601.htm, November 2014.